165 related articles for article (PubMed ID: 1646903)
1. The correlation between the immunohistochemical expression of DF3 antigen and serum CA15-3 in breast cancer patients.
Ohuchi N; Sato S; Akimoto M; Taira Y; Matoba N; Takahashi K; Mori S
Jpn J Surg; 1991 Mar; 21(2):129-37. PubMed ID: 1646903
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of an immunoradiometric assay for CA15-3 antigen associated with human mammary carcinomas: comparison with carcinoembryonic antigen.
Fujino N; Haga Y; Sakamoto K; Egami H; Kimura M; Nishimura R; Akagi M
Jpn J Clin Oncol; 1986 Dec; 16(4):335-46. PubMed ID: 3467106
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumor-associated antigens detected by monoclonal antibodies against the polypeptide core of mucin--comparison of antigen MUSE11 with CA15-3.
Hinoda Y; Kakiuchi H; Nakagawa N; Ohe Y; Sugiyama T; Tsujisaki M; Imai K; Yachi A
Gastroenterol Jpn; 1992 Jun; 27(3):390-5. PubMed ID: 1378032
[TBL] [Abstract][Full Text] [Related]
4. [An immunohistochemical study of various breast tissues using CA15-3 (MAb 115D8 and MAb DF3)].
Sekine H
Gan No Rinsho; 1987 Jul; 33(8):913-9. PubMed ID: 2441086
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibody DF3 correlates with tumor differentiation and hormone receptor status in breast cancer patients.
Lundy J; Thor A; Maenza R; Schlom J; Forouhar F; Testa M; Kufe D
Breast Cancer Res Treat; 1985; 5(3):269-76. PubMed ID: 2992647
[TBL] [Abstract][Full Text] [Related]
6. Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients.
Hayes DF; Sekine H; Ohno T; Abe M; Keefe K; Kufe DW
J Clin Invest; 1985 May; 75(5):1671-8. PubMed ID: 3889057
[TBL] [Abstract][Full Text] [Related]
7. Circulating DF3 and CA125 antigen levels in serum from patients with epithelial ovarian carcinoma.
Sekine H; Hayes DF; Ohno T; Keefe KA; Schaetzl E; Bast RC; Knapp R; Kufe DW
J Clin Oncol; 1985 Oct; 3(10):1355-63. PubMed ID: 2413181
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of tissue DF3 antigen and CA15-3 tumor marker in primary breast cancer.
Dimas C; Fragos-Plemenos M; Gennatas C; Kouskouni E; Kondi-Paphitis A
Eur J Gynaecol Oncol; 2000; 21(3):278-81. PubMed ID: 10949394
[TBL] [Abstract][Full Text] [Related]
9. Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer.
Hayes DF; Zurawski VR; Kufe DW
J Clin Oncol; 1986 Oct; 4(10):1542-50. PubMed ID: 2428949
[TBL] [Abstract][Full Text] [Related]
10. Reactivity of monoclonal antibody DF3 with a high molecular weight antigen expressed in human ovarian carcinomas.
Friedman EL; Hayes DF; Kufe DW
Cancer Res; 1986 Oct; 46(10):5189-94. PubMed ID: 3530435
[TBL] [Abstract][Full Text] [Related]
11. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors.
Kufe D; Inghirami G; Abe M; Hayes D; Justi-Wheeler H; Schlom J
Hybridoma; 1984; 3(3):223-32. PubMed ID: 6094338
[TBL] [Abstract][Full Text] [Related]
12. Expression of tumor-associated antigen (DF3) in atypical hyperplasias and in situ carcinomas of the human breast.
Ohuchi N; Page DL; Merino MJ; Viglione MJ; Kufe DW; Schlom J
J Natl Cancer Inst; 1987 Jul; 79(1):109-17. PubMed ID: 3298784
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of cancer antigen 15-3 (CA15-3) detected by monoclonal antibodies (115D8 and DF3) in exudative pleural effusions.
Shimokata K; Totani Y; Nakanishi K; Yamamoto M; Hasegawa Y; Kawatsu H; Sasou H; Murate T; Ichiyama S; Kurasawa T
Eur Respir J; 1988 Apr; 1(4):341-4. PubMed ID: 3165069
[TBL] [Abstract][Full Text] [Related]
14. Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a Cancer and Leukemia Group B study.
Hayes DF; Mesa-Tejada R; Papsidero LD; Croghan GA; Korzun AH; Norton L; Wood W; Strauchen JA; Grimes M; Weiss RB
J Clin Oncol; 1991 Jul; 9(7):1113-23. PubMed ID: 2045853
[TBL] [Abstract][Full Text] [Related]
15. Comparison of mammary serum antigen (MSA) and CA15-3 levels in the serum of patients with breast cancer.
Sacks NP; Stacker SA; Thompson CH; Collins JP; Russell IS; Sullivan JA; McKenzie IF
Br J Cancer; 1987 Dec; 56(6):820-4. PubMed ID: 2449238
[TBL] [Abstract][Full Text] [Related]
16. Differences in expression of SPan-1 and CA15-3 antigens in blood and tissues.
Ho JJ; Chung YS; Yuan M; Henslee JG; Kim YS
Int J Cancer; 1992 Nov; 52(5):693-700. PubMed ID: 1428228
[TBL] [Abstract][Full Text] [Related]
17. Comparison of serum CA15-3 and CEA in breast cancer.
Hou MF; Huang TJ; Hsieh JS; Huang YS; Huang CJ; Chan HM; Wang JY; Chen YL; Jong SB; Yang CC
Gaoxiong Yi Xue Ke Xue Za Zhi; 1995 Dec; 11(12):660-6. PubMed ID: 8551526
[TBL] [Abstract][Full Text] [Related]
18. Purification and characterization of a high molecular weight glycoprotein detectable in human milk and breast carcinomas.
Sekine H; Ohno T; Kufe DW
J Immunol; 1985 Nov; 135(5):3610-5. PubMed ID: 4045199
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of the usefulness of primary tumour expression of MCA and CA15-3 as prognostic indicators in breast carcinoma.
Byrne J; Horgan PG; England S; Callaghan J; Given HF
Eur J Surg Oncol; 1992 Jun; 18(3):230-4. PubMed ID: 1607033
[TBL] [Abstract][Full Text] [Related]
20. Effects of maturational agents on expression and secretion of two partially characterized high molecular weight milk-related glycoproteins in MCF-7 breast carcinoma cells.
Abe M; Kufe D
J Cell Physiol; 1986 Jan; 126(1):126-32. PubMed ID: 2418036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
